Vestmark Advisory Solutions, Inc. Argenx Se Transaction History

Vestmark Advisory Solutions, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 09, 2021	SELL	$257.11 - $319.92 $630,947 - $785,083	-2,454 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$268.3 - $380.31 $18,512 - $26,241	69 Added 2.89%	2,454 $676,000
Q4 2020 Feb 04, 2021	BUY	$248.13 - $308.36 $12,158 - $15,109	49 Added 2.1%	2,385 $701,000
Q3 2020 Oct 19, 2020	BUY	$215.51 - $272.51 $20,042 - $25,343	93 Added 4.15%	2,336 $613,000
Q2 2020 Aug 13, 2020	SELL	$127.44 - $232.72 $19,753 - $36,071	-155 Reduced 6.46%	2,243 $505,000
Q1 2020 May 06, 2020	BUY	$108.83 - $165.23 $260,974 - $396,221	2,398 New	2,398 $316,000
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $243,131 - $374,563	-2,281 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$113.31 - $150.51 $19,489 - $25,887	172 Added 8.16%	2,281 $260,000
Q2 2019 Aug 20, 2019	BUY	$115.0 - $141.58 $3,795 - $4,672	33 Added 1.59%	2,109 $299,000
Q1 2019 May 14, 2019	BUY	$98.85 - $134.59 $205,212 - $279,408	2,076 New	2,076 $259,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Vestmark Advisory Solutions, Inc., based on Form 13F filings with the SEC.

Stay updated on Vestmark Advisory Solutions, Inc. with notifications on news.